Study for Evaluation of Efficacy and Safety of SH L 749 to Indolent B-cell Non-Hodgkin's Lymphoma

• Status: Completed
• Trial end date: 2005-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to investigate the antitumor effect and safety of the product for relapsed or refractory indolent B-cell non-Hodgkin's lymphomas.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bayer
• Treatments: Antibodies, Monoclonal

Criteria

Inclusion Criteria:

• Platelet counts of >/= 100,000/mm3

• Absolute neutrophil counts of >/= 1,200/mm3

• Bone marrow involvement < 25%

Exclusion Criteria:

• Patients who received hematopoietic stem cell transplantation, including bone marrow transplantation, peripheral blood stem cell transplantation, etc.

• Patients presenting with marked bone marrow hypocellularity (any suspected bone marrow hypocellularity should be confirmed by bone marrow biopsy)

• Patients with previous myocardial infarction within the past 1 year, with heart disease that requires treatment or with pulmonary dysfunction

• Patients with serious concomitant diseases (cardiac failure, renal failure, etc.)